Challenge to Predict Mobilized Peripheral Blood Stem Cells on the Fourth Day of Granulocyte Colony-Stimulating Factor Treatment in Healthy Donors: Predictive Value of Basal CD34+ Cell and Platelet Counts

Martino, Massimo; Gori, Mercedes; Moscato, Tiziana; Naso, Virginia; Ferreri, Anna Maria; Provenzano, Fabio; Loteta, Barbara; Sanguedolce, Maria Cristina; Console, Giuseppe; Dattola, A.; Pucci, Giulia; Gentile, Massimo; Morabito, Antonella; Recchia, Anna Grazia; Tripepi, Giovanni; Pitino, Annalisa

doi:10.1016/j.bbmt.2019.04.011

Cited by 10 publications

(11 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study by Basak et al, no correlation was found between CD34+ cell dose and WBC count on the first day of plerixafor injection (30), which is inconsistent with our results. CD34+ cell count before collection is the most accurate and reliable predictor of mobilization rate (25,31,32), which is also confirmed by the present study's data.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Evaluation of CD34+ Cell Count at Different Time Points Following Plerixafor Administration in Autologous Hematopoietic Stem Cell Transplantation

et al. 2022

View full text Add to dashboard Cite

Background: In apheresis, collecting an adequate number of CD34+ cells is required for successful autologous hematopoietic stem cell transplantation (auto-HSCT) procedure. It is difficult to harvest a sufficient number of stem cells in certain patients due to their old age and history of intensive chemotherapy. Plerixafor could mobilize stem cells and facilitate peripheral blood hematopoietic stem cell collection. However, not enough information is available on the appropriate time intervals from plerixafor administration to apheresis. Objectives: In this study, we aimed at evaluating the level of peripheral blood CD34+ cells at plerixafor administration time and every three hours to identify the peak time of circulating CD34+ cells. Methods: Circulating CD34+ cells were enumerated by flow cytometry on day 4 post mobilization. Plerixafor was administered to patients with poor mobilization based on the count of peripheral blood hematopoietic stem cells. The number of circulating CD34+ cells was evaluated before and 3, 6, 9, and 12 hours after plerixafor administration to assess the time it takes for stem cells to reach their peak level. Results: The highest level of stem cell concentration was found in 9 hours after plerixafor administration with an increasing trend. A statistically significant relationship was also observed between factors including platelet count on the first day of GCSF injection and the day of stem cell infusion, leukocyte count on admission, and basal levels of CD34+ cells in peripheral blood and the amount of harvested stem cells. Conclusions: We demonstrated that plerixafor causes an incremental trend in CD34+ cells mobilization, reaching its peak after 9 hours. Further research should be performed to provide insights into graft cells’ population and hematologic and immunological recovery.

show abstract

Section: Discussionsupporting

confidence: 90%

“…The study by Martino et al supports the significant effect of platelet count before G-CSF administration in healthy donors on the quantity of collected CD34+ cells (25). In another study, low platelet counts before apheresis in patients with multiple myeloma were significantly associated with poor mobilization outcomes (26).…”

Section: Discussionmentioning

confidence: 86%

Evaluation of CD34+ Cell Count at Different Time Points Following Plerixafor Administration in Autologous Hematopoietic Stem Cell Transplantation

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Considering demographic data and CBC parameters, our algorithm did not reveal a reliable tool to identify poor mobilizers before G-CSF application [ 6 ]. Besides genetic polymorphisms, other parameters (e.g., basal CD34+ count) might also be useful predictors of mobilization performance [ 28 – 31 ].…”

Section: Discussionmentioning

confidence: 99%

Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial

Hölig

Schmidt

Hütter³

et al. 2020

Bone Marrow Transplant

View full text Add to dashboard Cite

We conducted a prospective clinical trial to investigate the safety and efficacy of plerixafor (P) in allogeneic peripheral blood stem cells (PBSC) donors with poor mobilization response to standard-dose granulocyte colony-stimulating factor (G-CSF), defined by <2 × 10 6 CD34 + cells/kg recipient body-weight (CD34+/kg RBW) after 1st apheresis. A single dose of 240 µg/kg P was injected subcutaneously at 10 p.m. on the day of the 1st apheresis. Thirty-seven allogeneic PBSC donors underwent study treatment. The median CD34+ count in peripheral blood was 15/µl on Day 1 after G-CSF alone, versus 44/µl on Day 2 after G-CSF plus P ( p < 0.001). The median yield of CD34+ cells was 1.1 × 10 8 on Day 1 and 2.8 × 10 8 on Day 2. In contrast to a median yield of only 1.31 × 10 6 CD CD34+/kg RBW on Day 1, triggering study inclusion, a median of 3.74 × 10 6 CD CD34+/kg RBW were collected with G-CSF plus P on Day 2. Of 37 donors, 21 reached the target cell count of >4.5 × 10 6 CD34+/kg RBW (57%, 95%CI 40–73%). No donor experienced a severe adverse event requiring treatment. In conclusion, P might be considered on a case-by-case basis for healthy allogeneic donors with very poor stem cell mobilization success after G-CSF.

show abstract

“…Of the 17 studies that assessed the association between CD34 + cell yield and donor gender 12 (71%) reported higher CD34+ cell yields in males (9, 10, 12, 14, 17–19, 25, 28, 30, 43, 44) but the remaining five studies (29%) found no association (6, 15, 16, 24, 29). Of the 20 studies that assessed blood CD34+ cell concentration, eight (42%) reported higher concentrations in males (9, 30, 32, 34, 36, 37, 39, 45) whereas 12 (59%) reported no significant effect of gender (6, 17, 21, 22, 31, 33, 35, 38, 40–42, 46).…”

Section: Resultsmentioning

confidence: 99%

“…Seven of nine studies reported an association between high BMI and higher blood CD34+ concentration (6, 26, 30, 32, 37, 42, 46). None of the seven studies that assessed donor height reported an association with either CD34+ cell yield (20, 25, 29), or blood CD34+ cell concentration (36, 38, 40, 41). All four of the studies that assessed the differences in weight between donor and recipients reported an association between donors having greater positive weight differences and higher CD34 + cell yield (6, 8, 14, 28).…”

Section: Resultsmentioning

confidence: 99%

Scoping review of factors associated with stem cell mobilisation and collection in allogeneic stem cell donors

Peck,

Knapp-Wilson,

Burley

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: There is a large inter-individual variation in CD34+ cell yield after G-CSF mobilisation and collection from peripheral blood in healthy allogenic haematopoietic stem cell donors. Donor characteristics including gender and age, baseline and precollection blood results, mobilisation factors and collection factors have been associated with CD34+ cell concentration in the blood after G-CSF mobilisation and/or CD34+ cell yield after collection. Since the literature reporting these associations is heterogeneous, we here clarify the determinants of CD34+ cell concentration and yield through a scoping literature review. Materials and Methods: MEDLINE, Embase, PubMed and Stem Cell Evidence were searched for studies published between 2000 and 2023. The inclusion criteria were studies of allogeneic donors undergoing G-CSF mobilisation and peripheral blood stem cell collection (PBSC). Eligible studies assessed an outcome of mobilisation or collection efficacy, indicated by the blood CD34+ cell concentration after 4 or 5 days of G-CSF treatment and/or CD34+ cell yield in the first PBSC collection after mobilisation. Included studies assessed associations between these outcomes and donor factors(such as age, gender, weight, ethnicity), mobilisation factors (G-CSF scheduling or dose), collection factors (venous access, processed blood volume) and laboratory factors (such as blood cell counts at baseline and after mobilisation). Results: The 51 eligible studies evaluated between 23 and 20,884 donors. 43 studies were retrospective, 32 assessed blood CD34+ cell concentration after mobilisation and 37 assessed CD34+ cell yield. In studies that recorded both outcomes, blood CD34+ cell concentration always predicted CD34+ cell yield. The most frequently assessed factor was donor age for which most studies reported that younger donors had a higher blood CD34+ cell concentration and CD34+ cell yield. Non-European ancestry was associated with both higher blood CD34+ cell concentration and yield although this finding was inconsistent. Conclusions: There remains poor consensus about the best predictors of blood CD34+ cell concentration and yield that requires further prospective study, particularly of the role of donor ancestry. The current focus on donor gender as a major predictor may require re-evaluation

show abstract

Challenge to Predict Mobilized Peripheral Blood Stem Cells on the Fourth Day of Granulocyte Colony-Stimulating Factor Treatment in Healthy Donors: Predictive Value of Basal CD34+ Cell and Platelet Counts

Cited by 10 publications

References 36 publications

Evaluation of CD34+ Cell Count at Different Time Points Following Plerixafor Administration in Autologous Hematopoietic Stem Cell Transplantation

Evaluation of CD34+ Cell Count at Different Time Points Following Plerixafor Administration in Autologous Hematopoietic Stem Cell Transplantation

Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial

Scoping review of factors associated with stem cell mobilisation and collection in allogeneic stem cell donors

Contact Info

Product

Resources

About